tomorrow's science, now
TRUE INNOVATION
The Bloodrops® therapy is based on breakthrough research spanning two decades. Our science is backed by over 20 high-impact factor scientific publications, it has been included in multiple books on regenerative medicine and has been presented many times in worldwide forums. The innovation is based on the use of a personalized cocktail of autologous growth factors (HYPPP®) which are naturally produced by blood cells outside the body, through a process that faithfully mimics the wound environment. This unique proprietary cocktail is entirely cell-free and contains over 100 unique growth factors that actively stimulate cell repair through new collagen synthesis, blood vessel development and improvement of skin elasticity.
roots of the discovery
Building upon more than 20 years of research and clinical experience on the field of regenerative medicine and chronic wound treatment, the Bloodrops® formula was created by world renowned plastic-reconstructive surgeon Dr. Hektor Panayi MD PD PhD (greek - Ektoras Hadjipanayi). This breakthrough discovery uses a proprietary composition that allows maximal delivery of blood-derived growth factors for home therapy, and is the first commercially available personalized and bioactive treatment for skin regeneration.
​
The science backing the Bloodrops® formula is backed by over 20 peer-reviewed publications in world-class scientific journals and books on regenerative medicine, as well as multiple international awards such as the German Prize for Biotechnology 2013 and Science4Life Prize 2016.
solid science
SCIENTIFIC PUBLICATIONS
Controlling Physiological Angiogenesis by Hypoxia-Induced Signaling.
Journal of Controlled Release, July, 2010
E.Hadjipanayi, R.A.Brown, V.Mudera, D.Deng, W.Liu, U.Cheema
PMID: 20538024
​
First Implantable Device for Hypoxia-Mediated Angiogenic Induction.
J Control Release. 2011 Aug 10;153(3):217-24.
E.Hadjipanayi, U.Cheema, V.Mudera, D.Deng, W.Liu, R.A.Brown
PMID: 21458514
Injectable System for Spatio-temporally controlled Delivery of Hypoxia-Induced Angiogenic Signalling.
J Control Release, 2012, Aug 10:161(3);852-60
E.Hadjipanayi , Cheema U., Hopfner U., Bauer AT, Moog P, , Machens HG, Schilling AF
PMID: 22634070
​
Cell-free Carrier System for Localized Delivery of Peripheral Blood Cell-Derived Engineered Factor Signaling: Towards Development of a One-Step Device for Autologous Angiogenic Therapy.
J Control Release. 2013 Jul 10;169(1-2):91-102
Hadjipanayi E, Bauer AT, Moog P, Salgin B, Kuekrek H, Fersch B, Hopfner U, Meissner T, Schlüter A, Ninkovic M, Machens HG, Schilling AF.
PMID: 23603614
​
Regeneration through autologous hypoxia preconditioned plasma.
Organogenesis. 2014 Apr-Jun;10(2):164-9. doi: 10.4161/org.29208. Epub 2014 May 15.
Hadjipanayi E, Schilling AF.
PMID: 24831225
​
Hypoxia-based strategies for angiogenic induction: the dawn of a new era for ischemia therapy and tissue regeneration.
Organogenesis. 2013 Oct 1;9(4):261-72. doi: 10.4161/org.25970. Epub 2013 Aug 8.
Hadjipanayi E, Schilling AF.
PMID: 23974216
​
The Fibrin Matrix Regulates Angiogenic Responses within the Hemostatic Microenvironment through Biochemical Control.
PLoS One. 2015 Aug 28;10(8):e0135618. doi: 10.1371/journal.pone.0135618. eCollection 2015.
Hadjipanayi E, Kuhn PH, Moog P, Bauer AT, Kuekrek H, Mirzoyan L, Hummel A, Kirchhoff K, Salgin B, Isenburg S, Dornseifer U, Ninkovic M, Machens HG, Schilling AF.
PMID: 26317771
​
In Vitro Characterization of Hypoxia Preconditioned Serum (HPS)-Fibrin Hydrogels: Basis for an Injectable Biomimetic Tissue Regeneration Therapy.
J.Funct Biomater. 2019 May 13;10(2):22. doi: 10.3390/jfb10020022.
Hadjipanayi E, Moog P, Bekeran S, Kirchhoff K, Berezhnoi A, Aguirre J, Bauer AT, Kükrek H, Schmauss D, Hopfner U, Isenburg S, Ntziachristos V, Ninkovic M, Machens HG, Schilling AF, Dornseifer U.
PMID: 31086048
​
Comparative Evaluation of the Angiogenic Potential of Hypoxia Preconditioned Blood-Derived Secretomes and Platelet-Rich Plasma: An In Vitro Analysis.
Biomedicines. 2020 Jan 16;8(1):16. doi: 10.3390/biomedicines8010016.
Moog P, Kirchhoff K, Bekeran S, Bauer AT, von Isenburg S, Dornseifer U, Machens HG, Schilling AF, Hadjipanayi E.
PMID: 31963131
​
Use of Oral Anticoagulation and Diabetes Do Not Inhibit the Angiogenic Potential of Hypoxia Preconditioned Blood-Derived Secretomes.
Biomedicines. 2020 Aug 11;8(8):283. doi: 10.3390/biomedicines8080283.
Moog P, Jensch M, Hughes J, Salgin B, Dornseifer U, Machens HG, Schilling AF, Hadjipanayi E.
PMID: 32796694
​
Hypoxia Preconditioned Serum (HPS)-Hydrogel Can Accelerate Dermal Wound Healing in Mice-An In Vivo Pilot Study.
Biomedicines. 2022 Jan 14;10(1):176. doi: 10.3390/biomedicines10010176.
Jiang J, Kraneburg U, Dornseifer U, Schilling AF, Hadjipanayi E, Machens HG, Moog P.
PMID: 35052855
​
Effect of Hypoxia Preconditioned Secretomes on Lymphangiogenic and Angiogenic Sprouting: An in Vitro Analysis.
Biomedicines. 2020 Sep 20;8(9):365. doi: 10.3390/biomedicines8090365.
Moog P, Schams R, Schneidinger A, Schilling AF, Machens HG, Hadjipanayi E, Dornseifer U.
PMID: 32962277
​
Hypoxia Preconditioned Serum (HPS) Promotes Osteoblast Proliferation, Migration and Matrix Deposition.
Biomedicines. 2022 Jul 7;10(7):1631. doi: 10.3390/biomedicines10071631.
Jiang J, Röper L, Alageel S, Dornseifer U, Schilling AF, Hadjipanayi E, Machens HG, Moog P.
PMID: 35884936
​
Identification of Key Factors in Deep O2 Cell Perfusion for Vascular Tissue-Engineering.
Int.J.Artif.Organs.,2009, 32 (6):318-28.
U.Cheema, E.Hadjipanayi, N.Tamimi, B.Alp, V.Mudera, R.A Brown.
